Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study-Reference-Cited by-同舟云学术

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Published:2008-06 Issue:9630 Volume:371 Page:2085-2092
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Comi G,Pulizzi A,Rovaris M,Abramsky O,Arbizu T,Boiko A,Gold R,Havrdova E,Komoly S,Selmaj KW,Sharrack B,Filippi M

Publisher

Elsevier BV

Subject

General Medicine

Reference35 articles.

1. A pilot trial of Cop-1 in exacerbating-remitting multiple sclerosis;Bornstein;N Engl J Med,1987

2. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial;Johnson;Neurology,1995

3. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability;Johnson;Neurology,1998

4. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis;Comi;Ann Neurol,2001

5. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. clinical results of a multicenter, randomized, double blind, placebo-controlled trial;Neurology,1993

Cited by 230 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1/PD-L1 inhibitors;Journal for ImmunoTherapy of Cancer;2024-01

2. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-11-30

3. Methyl-CpG-Binding Protein 2 Emerges as a Central Player in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders;Cellular and Molecular Neurobiology;2023-11

4. Complex regulation of alarmins S100A8/A9 and secretion via gasdermin D pores exacerbates autoinflammation in familial Mediterranean fever;Journal of Allergy and Clinical Immunology;2023-07

5. Recent advances in clinical trials targeting the kynurenine pathway;Pharmacology & Therapeutics;2022-08